A blood test has been shown to accurately identify patients with amyotrophic lateral sclerosis at early stages, which could ...

Gleason, who was diagnosed with amyotrophic lateral sclerosis (ALS) in 2011 when he was 33 years old, has become an advocate ...

Launched in 2020 to more quickly bring to market an effective medicine for amyotrophic lateral sclerosis, the HEALEY Platform ...

Neuralink rival Synchron is connecting its brain–computer interface with consumer technologies to allow people with paralysis ...

SALT LAKE CITY, Sept. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage ...

The Phase 1 clinical trial is expected to enroll about 60 participants to test how safe and well tolerated multiple doses of ...

People with rare genetic variants linked to degenerative brain disorders like Parkinson's disease are at increased risk of ...

A 59-year-old man with amyotrophic lateral sclerosis has realized his dream of walking through the Sassi of Matera thanks to ...

China’s National Intellectual Property Administration has issued notification to grant patent to PolTREG Chinese patent covers intrathecal administration of PolTREG’s PTG-007 Treg cell therapy to ...

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, will be meeting in ...

PORTLAND, Maine — Early Sunday morning, hundreds showed up to attend an annual Walk to Defeat ALS in Portland. Amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, is a progressive ...